Spots Global Cancer Trial Database for belinostat
Every month we try and update this database with for belinostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | NCT04703920 | Metastatic Brea... Metastatic Cast... Metastatic Ovar... | Talazoparib Belinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | NCT02737046 | Adult T-cell Le... ATLL | Belinostat Zidovudine Interferon-Alfa... Pegylated Inter... | 18 Years - | University of Miami | |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | NCT02381548 | Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult... | Adavosertib Belinostat Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | NCT00873119 | Carcinoma of Un... | belinostat, car... carboplatin, pa... | 18 Years - | Valerio Therapeutics | |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01839097 | Peripheral T-ce... | Belinostat CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT00865969 | Peripheral T-ce... | Belinostat | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Belinostat in Treating Patients With Myelodysplastic Syndromes | NCT00357162 | de Novo Myelody... Previously Trea... Secondary Myelo... | belinostat | 18 Years - | National Cancer Institute (NCI) | |
| Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | NCT02875002 | Relapsed and Re... Lymphoma | volasertib belinostat | 18 Years - | Yale University | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | NCT00334789 | Adult Solid Neo... | Belinostat Isotretinoin Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT00303953 | Recurrent Adult... Recurrent Adult... | belinostat | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | NCT00274651 | Cutaneous T-Cel... Peripheral T-Ce... Non-Hodgkin's L... | belinostat | 18 Years - | Valerio Therapeutics | |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | NCT06406465 | Carcinoma, Neur... Tumor, Neuroend... Tumors, Neuroen... Neuroendocrine;... Small Cell; Rec... | Belinostat Cisplatin Etoposide | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | NCT01686165 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | belinostat rituximab yttrium Y 90 ib... | 18 Years - | University of Arizona | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | NCT05627245 | Recurrent B-Cel... Recurrent Diffu... Recurrent Non-H... Recurrent Prima... Recurrent T-Cel... Recurrent Trans... Refractory B-Ce... Refractory Diff... Refractory Non-... Refractory Prim... Refractory T-Ce... Refractory Tran... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Pharmacokinetic... Positron Emissi... Tazemetostat | 18 Years - | National Cancer Institute (NCI) | |
| MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | NCT02137759 | Glioblastoma Mu... | Standard Radiat... Standard Temozo... Belinostat | 18 Years - | Emory University | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | NCT00878722 | Acute Myeloid L... | PXD101 idarubicin | 18 Years - | Valerio Therapeutics | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | NCT00334789 | Adult Solid Neo... | Belinostat Isotretinoin Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer | NCT01583777 | Advanced Cancer | Belinostat | 18 Years - | Acrotech Biopharma Inc. | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | NCT00301756 | Fallopian Tube ... Primary Periton... Recurrent Borde... Recurrent Ovari... Stage III Borde... Stage III Ovari... Stage IV Border... Stage IV Ovaria... | Belinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | NCT04184869 | Solid Tumor Hematological M... | Belinostat Atazanavir | 18 Years - | Acrotech Biopharma Inc. | |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma | NCT05154994 | Infiltrating Ur... Locally Advance... Metastatic Urot... Unresectable Ur... | Belinostat Durvalumab | 18 Years - | University of Utah | |
| Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | NCT02737046 | Adult T-cell Le... ATLL | Belinostat Zidovudine Interferon-Alfa... Pegylated Inter... | 18 Years - | University of Miami | |
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | NCT00365053 | Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes... | belinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | NCT00431340 | Multiple Myelom... | PXD101 | 18 Years - | Valerio Therapeutics | |
| Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | NCT00873119 | Carcinoma of Un... | belinostat, car... carboplatin, pa... | 18 Years - | Valerio Therapeutics | |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | NCT02737046 | Adult T-cell Le... ATLL | Belinostat Zidovudine Interferon-Alfa... Pegylated Inter... | 18 Years - | University of Miami | |
| PXD101 in Treating Patients With Acute Myeloid Leukemia | NCT00357032 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Untreated Adult... | belinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | NCT01075425 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Chronic Myeloge... | bortezomib belinostat laboratory biom... western blottin... pharmacological... flow cytometry | 18 Years - | Virginia Commonwealth University | |
| Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | NCT00878722 | Acute Myeloid L... | PXD101 idarubicin | 18 Years - | Valerio Therapeutics | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | NCT00431340 | Multiple Myelom... | PXD101 | 18 Years - | Valerio Therapeutics | |
| MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | NCT02137759 | Glioblastoma Mu... | Standard Radiat... Standard Temozo... Belinostat | 18 Years - | Emory University | |
| Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | NCT00878722 | Acute Myeloid L... | PXD101 idarubicin | 18 Years - | Valerio Therapeutics | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00321594 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | belinostat | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
